Thank you, Chair.
Ms. Farquharson, there have been some evolving conversations around the “per substance” approach versus the risk management reporting. I'm wondering if you could clarify the difference just so that we understand exactly how CEPA approaches risk management versus the per substance approach that we're hearing now, equated as almost two different things.